XML 77 R58.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2024 | Apr. 02, 2023
Sales by segment of business |  |
Sales to customers | $ 21,383 | $ 20,894
Percent Change (as a percent) | 2.30% |
U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 11,620 | 10,782
Percent Change (as a percent) | 7.80% |
International |  |
Sales by segment of business |  |
Sales to customers | $ 9,763 | 10,112
Percent Change (as a percent) | (3.40%) |
MEDTECH |  |
Sales by segment of business |  |
Sales to customers | $ 7,821 | 7,481
Percent Change (as a percent) | 4.50% |
MEDTECH | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 4,008 | 3,759
Percent Change (as a percent) | 6.60% |
MEDTECH | International |  |
Sales by segment of business |  |
Sales to customers | $ 3,813 | 3,722
Percent Change (as a percent) | 2.40% |
MEDTECH | Cardiovascular(2) |  |
Sales by segment of business |  |
Sales to customers | $ 1,806 | 1,503
Percent Change (as a percent) | 20.20% |
MEDTECH | Cardiovascular(2) | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,025 | 863
Percent Change (as a percent) | 18.80% |
MEDTECH | Cardiovascular(2) | International |  |
Sales by segment of business |  |
Sales to customers | $ 781 | 640
Percent Change (as a percent) | 22.10% |
MEDTECH | ELECTROPHYSIOLOGY |  |
Sales by segment of business |  |
Sales to customers | $ 1,344 | 1,092
Percent Change (as a percent) | 23.00% |
MEDTECH | ELECTROPHYSIOLOGY | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 692 | 571
Percent Change (as a percent) | 21.30% |
MEDTECH | ELECTROPHYSIOLOGY | International |  |
Sales by segment of business |  |
Sales to customers | $ 652 | 522
Percent Change (as a percent) | 24.90% |
MEDTECH | ABIOMED |  |
Sales by segment of business |  |
Sales to customers | $ 371 | 324
Percent Change (as a percent) | 14.50% |
MEDTECH | ABIOMED | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 303 | 264
Percent Change (as a percent) | 15.00% |
MEDTECH | ABIOMED | International |  |
Sales by segment of business |  |
Sales to customers | $ 67 | 60
Percent Change (as a percent) | 12.40% |
MEDTECH | OTHER CARDIOVASCULAR(2) |  |
Sales by segment of business |  |
Sales to customers | $ 92 | 87
Percent Change (as a percent) | 5.70% |
MEDTECH | OTHER CARDIOVASCULAR(2) | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 30 | 28
Percent Change (as a percent) | 3.30% |
MEDTECH | OTHER CARDIOVASCULAR(2) | International |  |
Sales by segment of business |  |
Sales to customers | $ 62 | 58
Percent Change (as a percent) | 6.90% |
MEDTECH | Orthopaedics |  |
Sales by segment of business |  |
Sales to customers | $ 2,340 | 2,245
Percent Change (as a percent) | 4.30% |
MEDTECH | Orthopaedics | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,448 | 1,363
Percent Change (as a percent) | 6.20% |
MEDTECH | Orthopaedics | International |  |
Sales by segment of business |  |
Sales to customers | $ 892 | 881
Percent Change (as a percent) | 1.30% |
MEDTECH | Orthopaedics | HIPS |  |
Sales by segment of business |  |
Sales to customers | $ 422 | 390
Percent Change (as a percent) | 8.10% |
MEDTECH | Orthopaedics | HIPS | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 270 | 241
Percent Change (as a percent) | 12.10% |
MEDTECH | Orthopaedics | HIPS | International |  |
Sales by segment of business |  |
Sales to customers | $ 152 | 149
Percent Change (as a percent) | 1.70% |
MEDTECH | Orthopaedics | KNEES |  |
Sales by segment of business |  |
Sales to customers | $ 401 | 368
Percent Change (as a percent) | 9.00% |
MEDTECH | Orthopaedics | KNEES | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 242 | 226
Percent Change (as a percent) | 6.90% |
MEDTECH | Orthopaedics | KNEES | International |  |
Sales by segment of business |  |
Sales to customers | $ 160 | 142
Percent Change (as a percent) | 12.30% |
MEDTECH | Orthopaedics | TRAUMA |  |
Sales by segment of business |  |
Sales to customers | $ 765 | 757
Percent Change (as a percent) | 1.00% |
MEDTECH | Orthopaedics | TRAUMA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 504 | 491
Percent Change (as a percent) | 2.80% |
MEDTECH | Orthopaedics | TRAUMA | International |  |
Sales by segment of business |  |
Sales to customers | $ 261 | 267
Percent Change (as a percent) | (2.30%) |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER |  |
Sales by segment of business |  |
Sales to customers | $ 752 | 729
Percent Change (as a percent) | 3.20% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 432 | 406
Percent Change (as a percent) | 6.50% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | International |  |
Sales by segment of business |  |
Sales to customers | $ 320 | 323
Percent Change (as a percent) | (0.90%) |
MEDTECH | Surgery |  |
Sales by segment of business |  |
Sales to customers | $ 2,416 | 2,434
Percent Change (as a percent) | (0.70%) |
MEDTECH | Surgery | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 987 | 975
Percent Change (as a percent) | 1.20% |
MEDTECH | Surgery | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,429 | 1,459
Percent Change (as a percent) | (2.00%) |
MEDTECH | Surgery | ADVANCED |  |
Sales by segment of business |  |
Sales to customers | $ 1,087 | 1,118
Percent Change (as a percent) | (2.80%) |
MEDTECH | Surgery | ADVANCED | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 446 | 444
Percent Change (as a percent) | 0.20% |
MEDTECH | Surgery | ADVANCED | International |  |
Sales by segment of business |  |
Sales to customers | $ 641 | 673
Percent Change (as a percent) | (4.70%) |
MEDTECH | Surgery | GENERAL |  |
Sales by segment of business |  |
Sales to customers | $ 1,330 | 1,316
Percent Change (as a percent) | 1.00% |
MEDTECH | Surgery | GENERAL | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 542 | 531
Percent Change (as a percent) | 2.10% |
MEDTECH | Surgery | GENERAL | International |  |
Sales by segment of business |  |
Sales to customers | $ 788 | 785
Percent Change (as a percent) | 0.30% |
MEDTECH | Vision |  |
Sales by segment of business |  |
Sales to customers | $ 1,258 | 1,300
Percent Change (as a percent) | (3.30%) |
MEDTECH | Vision | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 547 | 558
Percent Change (as a percent) | (1.80%) |
MEDTECH | Vision | International |  |
Sales by segment of business |  |
Sales to customers | $ 710 | 743
Percent Change (as a percent) | (4.40%) |
MEDTECH | Vision | CONTACT LENSES / OTHER |  |
Sales by segment of business |  |
Sales to customers | $ 910 | 953
Percent Change (as a percent) | (4.60%) |
MEDTECH | Vision | CONTACT LENSES / OTHER | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 438 | 444
Percent Change (as a percent) | (1.40%) |
MEDTECH | Vision | CONTACT LENSES / OTHER | International |  |
Sales by segment of business |  |
Sales to customers | $ 472 | 509
Percent Change (as a percent) | (7.40%) |
MEDTECH | Vision | SURGICAL |  |
Sales by segment of business |  |
Sales to customers | $ 348 | 347
Percent Change (as a percent) | 0.30% |
MEDTECH | Vision | SURGICAL | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 110 | 114
Percent Change (as a percent) | (3.70%) |
MEDTECH | Vision | SURGICAL | International |  |
Sales by segment of business |  |
Sales to customers | $ 238 | 233
Percent Change (as a percent) | 2.20% |
Innovative Medicine |  |
Sales by segment of business |  |
Sales to customers | $ 13,562 | 13,413
Percent Change (as a percent) | 1.10% |
Innovative Medicine | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 7,612 | 7,023
Percent Change (as a percent) | 8.40% |
Innovative Medicine | International |  |
Sales by segment of business |  |
Sales to customers | $ 5,950 | 6,390
Percent Change (as a percent) | (6.90%) |
Innovative Medicine | Immunology |  |
Sales by segment of business |  |
Sales to customers | $ 4,247 | 4,112
Percent Change (as a percent) | 3.30% |
Innovative Medicine | Immunology | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 2,453 | 2,448
Percent Change (as a percent) | 0.20% |
Innovative Medicine | Immunology | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,794 | 1,664
Percent Change (as a percent) | 7.90% |
Innovative Medicine | Immunology | REMICADE |  |
Sales by segment of business |  |
Sales to customers | $ 434 | 487
Percent Change (as a percent) | (10.90%) |
Innovative Medicine | Immunology | REMICADE | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 266 | 276
Percent Change (as a percent) | (3.90%) |
Innovative Medicine | Immunology | REMICADE | U.S. Exports |  |
Sales by segment of business |  |
Sales to customers | $ 27 | 41
Percent Change (as a percent) | (32.70%) |
Innovative Medicine | Immunology | REMICADE | International |  |
Sales by segment of business |  |
Sales to customers | $ 141 | 170
Percent Change (as a percent) | (17.20%) |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA |  |
Sales by segment of business |  |
Sales to customers | $ 554 | 537
Percent Change (as a percent) | 3.00% |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 254 | 271
Percent Change (as a percent) | (6.20%) |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | International |  |
Sales by segment of business |  |
Sales to customers | $ 299 | 266
Percent Change (as a percent) | 12.40% |
Innovative Medicine | Immunology | STELARA |  |
Sales by segment of business |  |
Sales to customers | $ 2,451 | 2,444
Percent Change (as a percent) | 0.30% |
Innovative Medicine | Immunology | STELARA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,396 | 1,451
Percent Change (as a percent) | (3.80%) |
Innovative Medicine | Immunology | STELARA | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,055 | 993
Percent Change (as a percent) | 6.20% |
Innovative Medicine | Immunology | TREMFYA |  |
Sales by segment of business |  |
Sales to customers | $ 808 | 640
Percent Change (as a percent) | 26.30% |
Innovative Medicine | Immunology | TREMFYA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 509 | 406
Percent Change (as a percent) | 25.40% |
Innovative Medicine | Immunology | TREMFYA | International |  |
Sales by segment of business |  |
Sales to customers | $ 299 | 234
Percent Change (as a percent) | 27.90% |
Innovative Medicine | Immunology | OTHER IMMUNOLOGY |  |
Sales by segment of business |  |
Sales to customers | $ 0 | 3
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | U.S. |  |
Sales by segment of business |  |
Sales to customers | 0 | 3
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | International |  |
Sales by segment of business |  |
Sales to customers | $ 0 | 0
Percent Change (as a percent) | 0.00% |
Innovative Medicine | Infectious Diseases |  |
Sales by segment of business |  |
Sales to customers | $ 821 | 1,586
Percent Change (as a percent) | (48.30%) |
Innovative Medicine | Infectious Diseases | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 324 | 392
Percent Change (as a percent) | (17.40%) |
Innovative Medicine | Infectious Diseases | International |  |
Sales by segment of business |  |
Sales to customers | $ 497 | 1,193
Percent Change (as a percent) | (58.40%) |
Innovative Medicine | Infectious Diseases | COVID-19 |  |
Sales by segment of business |  |
Sales to customers | $ 25 | 747
Percent Change (as a percent) | (96.60%) |
Innovative Medicine | Infectious Diseases | COVID-19 | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 0 | $ 0
Percent Change (as a percent) |  | 0.00%
Innovative Medicine | Infectious Diseases | COVID-19 | International |  |
Sales by segment of business |  |
Sales to customers | $ 25 | $ 747
Percent Change (as a percent) | (96.60%) |
Innovative Medicine | Infectious Diseases | EDURANT / rilpivirine |  |
Sales by segment of business |  |
Sales to customers | $ 323 | 280
Percent Change (as a percent) | 15.70% |
Innovative Medicine | Infectious Diseases | EDURANT / rilpivirine | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 8 | 9
Percent Change (as a percent) | (10.90%) |
Innovative Medicine | Infectious Diseases | EDURANT / rilpivirine | International |  |
Sales by segment of business |  |
Sales to customers | $ 315 | 271
Percent Change (as a percent) | 16.60% |
Innovative Medicine | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |
Sales by segment of business |  |
Sales to customers | $ 418 | 477
Percent Change (as a percent) | (12.30%) |
Innovative Medicine | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 314 | 378
Percent Change (as a percent) | (16.90%) |
Innovative Medicine | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | International |  |
Sales by segment of business |  |
Sales to customers | $ 104 | 99
Percent Change (as a percent) | 5.50% |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES( |  |
Sales by segment of business |  |
Sales to customers | $ 53 | 82
Percent Change (as a percent) | (35.10%) |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES( | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 2 | 5
Percent Change (as a percent) | (68.80%) |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES( | International |  |
Sales by segment of business |  |
Sales to customers | $ 52 | 77
Percent Change (as a percent) | (32.80%) |
Innovative Medicine | Neuroscience |  |
Sales by segment of business |  |
Sales to customers | $ 1,803 | 1,804
Percent Change (as a percent) | 0.00% |
Innovative Medicine | Neuroscience | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,054 | 978
Percent Change (as a percent) | 7.80% |
Innovative Medicine | Neuroscience | International |  |
Sales by segment of business |  |
Sales to customers | $ 749 | 826
Percent Change (as a percent) | (9.30%) |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate |  |
Sales by segment of business |  |
Sales to customers | $ 177 | 206
Percent Change (as a percent) | (14.10%) |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 41 | 70
Percent Change (as a percent) | (41.20%) |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | International |  |
Sales by segment of business |  |
Sales to customers | $ 136 | 136
Percent Change (as a percent) | (0.10%) |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |
Sales by segment of business |  |
Sales to customers | $ 1,056 | 1,044
Percent Change (as a percent) | 1.20% |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 765 | 713
Percent Change (as a percent) | 7.20% |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International |  |
Sales by segment of business |  |
Sales to customers | $ 292 | 331
Percent Change (as a percent) | (11.80%) |
Innovative Medicine | Neuroscience | SPRAVATO |  |
Sales by segment of business |  |
Sales to customers | $ 225 | 131
Percent Change (as a percent) | 72.20% |
Innovative Medicine | Neuroscience | SPRAVATO | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 191 | 111
Percent Change (as a percent) | 71.50% |
Innovative Medicine | Neuroscience | SPRAVATO | International |  |
Sales by segment of business |  |
Sales to customers | $ 34 | 20
Percent Change (as a percent) | 76.10% |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE |  |
Sales by segment of business |  |
Sales to customers | $ 345 | 423
Percent Change (as a percent) | (18.50%) |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 58 | 84
Percent Change (as a percent) | (31.10%) |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | International |  |
Sales by segment of business |  |
Sales to customers | $ 287 | 339
Percent Change (as a percent) | (15.50%) |
Innovative Medicine | Oncology |  |
Sales by segment of business |  |
Sales to customers | $ 4,814 | 4,112
Percent Change (as a percent) | 17.10% |
Innovative Medicine | Oncology | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 2,383 | 1,889
Percent Change (as a percent) | 26.20% |
Innovative Medicine | Oncology | International |  |
Sales by segment of business |  |
Sales to customers | $ 2,430 | 2,223
Percent Change (as a percent) | 9.30% |
Innovative Medicine | Oncology | CARVYKTI |  |
Sales by segment of business |  |
Sales to customers | $ 157 | 72
Innovative Medicine | Oncology | CARVYKTI | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 140 | 70
Percent Change (as a percent) | 99.80% |
Innovative Medicine | Oncology | CARVYKTI | International |  |
Sales by segment of business |  |
Sales to customers | $ 16 | 2
Innovative Medicine | Oncology | DARZALEX |  |
Sales by segment of business |  |
Sales to customers | $ 2,692 | 2,264
Percent Change (as a percent) | 18.90% |
Innovative Medicine | Oncology | DARZALEX | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,464 | 1,191
Percent Change (as a percent) | 22.90% |
Innovative Medicine | Oncology | DARZALEX | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,228 | 1,072
Percent Change (as a percent) | 14.50% |
Innovative Medicine | Oncology | ERLEADA |  |
Sales by segment of business |  |
Sales to customers | $ 689 | 542
Percent Change (as a percent) | 27.00% |
Innovative Medicine | Oncology | ERLEADA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 285 | 249
Percent Change (as a percent) | 14.10% |
Innovative Medicine | Oncology | ERLEADA | International |  |
Sales by segment of business |  |
Sales to customers | $ 404 | 293
Percent Change (as a percent) | 38.00% |
Innovative Medicine | Oncology | IMBRUVICA |  |
Sales by segment of business |  |
Sales to customers | $ 784 | 827
Percent Change (as a percent) | (5.20%) |
Innovative Medicine | Oncology | IMBRUVICA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 265 | 270
Percent Change (as a percent) | (1.50%) |
Innovative Medicine | Oncology | IMBRUVICA | International |  |
Sales by segment of business |  |
Sales to customers | $ 518 | 557
Percent Change (as a percent) | (7.00%) |
Innovative Medicine | Oncology | ZYTIGA / abiraterone acetate |  |
Sales by segment of business |  |
Sales to customers | $ 181 | 245
Percent Change (as a percent) | (25.90%) |
Innovative Medicine | Oncology | ZYTIGA / abiraterone acetate | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 9 | 16
Percent Change (as a percent) | (41.30%) |
Innovative Medicine | Oncology | ZYTIGA / abiraterone acetate | International |  |
Sales by segment of business |  |
Sales to customers | $ 172 | 229
Percent Change (as a percent) | (24.80%) |
Innovative Medicine | Oncology | OTHER ONCOLOGY |  |
Sales by segment of business |  |
Sales to customers | $ 178 | 99
Percent Change (as a percent) | 80.20% |
Innovative Medicine | Oncology | OTHER ONCOLOGY | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 119 | 35
Innovative Medicine | Oncology | OTHER ONCOLOGY | International |  |
Sales by segment of business |  |
Sales to customers | $ 60 | 64
Percent Change (as a percent) | (6.10%) |
Innovative Medicine | Oncology | Tecvayli |  |
Sales by segment of business |  |
Sales to customers | $ 133 | 63
Innovative Medicine | Oncology | Tecvayli | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 101 | 57
Percent Change (as a percent) | 76.70% |
Innovative Medicine | Oncology | Tecvayli | International |  |
Sales by segment of business |  |
Sales to customers | $ 33 | 6
Innovative Medicine | Pulmonary Hypertension |  |
Sales by segment of business |  |
Sales to customers | $ 1,049 | 872
Percent Change (as a percent) | 20.20% |
Innovative Medicine | Pulmonary Hypertension | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 766 | 600
Percent Change (as a percent) | 27.50% |
Innovative Medicine | Pulmonary Hypertension | International |  |
Sales by segment of business |  |
Sales to customers | $ 283 | 272
Percent Change (as a percent) | 4.10% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT |  |
Sales by segment of business |  |
Sales to customers | $ 524 | 440
Percent Change (as a percent) | 19.10% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 356 | 273
Percent Change (as a percent) | 30.40% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT | International |  |
Sales by segment of business |  |
Sales to customers | $ 169 | 167
Percent Change (as a percent) | 0.80% |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI |  |
Sales by segment of business |  |
Sales to customers | $ 468 | 362
Percent Change (as a percent) | 29.20% |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 392 | 304
Percent Change (as a percent) | 29.00% |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | International |  |
Sales by segment of business |  |
Sales to customers | $ 76 | 58
Percent Change (as a percent) | 30.70% |
Innovative Medicine | Pulmonary Hypertension | Other |  |
Sales by segment of business |  |
Sales to customers | $ 56 | 70
Percent Change (as a percent) | (19.50%) |
Innovative Medicine | Pulmonary Hypertension | Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 18 | 23
Percent Change (as a percent) | (24.60%) |
Innovative Medicine | Pulmonary Hypertension | Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 39 | 47
Percent Change (as a percent) | (16.90%) |
Innovative Medicine | Cardiovascular / Metabolism / Other |  |
Sales by segment of business |  |
Sales to customers | $ 829 | 927
Percent Change (as a percent) | (10.60%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 631 | 715
Percent Change (as a percent) | (11.70%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 197 | 212
Percent Change (as a percent) | (7.00%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other |  |
Sales by segment of business |  |
Sales to customers | $ 311 | 349
Percent Change (as a percent) | (11.00%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 114 | 137
Percent Change (as a percent) | (17.10%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 197 | 212
Percent Change (as a percent) | (7.00%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO |  |
Sales by segment of business |  |
Sales to customers | $ 518 | 578
Percent Change (as a percent) | (10.40%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 518 | 578
Percent Change (as a percent) | (10.40%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | International |  |
Sales by segment of business |  |
Sales to customers | $ 0 | $ 0
Percent Change (as a percent) | 0.00% |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ElectrophysiologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_AbiomedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OtherCardiovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_COVID19Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPRAVATOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CARVYKTIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ERLEADAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TecvayliMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |